Scientists have reached a proof-of-concept milestone in a difficult part of HIV vaccine design: Phase 1 human trials repeatedly expanded VRC01-class precursors, early immune cells linked to antibodies aimed at HIV's CD4-binding site. The target is a class of broadly neutralizing antibodies, but the finding is not evidence that a protective vaccine has been achieved.
The review, a peer-reviewed journal contribution reported as an e-publication ahead of print in 2026, brings together Phase 1 human trials of germline-targeting immunogens with preclinical work on shaping, polishing, dosing and delivery. Its stated approach is to relate those design differences to VRC01-class responses and to later shaping and polishing steps.
Two designs, two different trade-offs
One pattern stands out. Smaller gp120-based immunogens have higher affinity for the relevant precursors and recruit larger, more diverse VRC01-class pools. In plain terms, they cast a wider net at the start of the response.
Native-like trimers show a different profile. They prime fewer lineages, but the lineages they engage are described as having more on-track somatic hypermutation, early glycan accommodation and neutralization of heterologous viruses. The response is narrower at the lineage stage, while showing more of the molecular changes associated with continued maturation.
Taken together, the findings make immunogen choice a balancing act. Smaller gp120-based designs favor the breadth of precursor recruitment, while native-like trimers favor maturation-related features. The review's preclinical focus is therefore on shaping and polishing the response, rather than treating either design as the end point.
The next stage is harder
Reaching the precursors is only the opening move. The authors identify the next challenge as inducing strong serum antibodies and memory B cells with both breadth and potency. The review therefore does not show that the precursor expansion in Phase 1 has produced durable, broadly neutralizing serum antibodies or memory responses.
Preclinical work is concentrated on what comes after priming: selecting shaping and polishing immunogens, testing alternative dosing, and trying controlled-release or mRNA-LNP delivery platforms to extend maturation. These approaches are aimed at keeping the antibody response moving through the needed stages over multidose regimens.
The authors say future regimens will have to optimize adjuvants, delivery systems and sequential immunogen design while sustaining affinity maturation across multiple doses. The review leaves unresolved whether these efforts can produce durable antibody responses that are both broad and potent.
What the review can answer
This is an overview of the evidence, not a report of a single vaccine efficacy trial. The supplied record describes Phase 1 human trials alongside preclinical work, but provides no included-study count, participant or animal total, common statistical synthesis, or study-level comparative estimate of protection. Those gaps limit what can be concluded about one immunogen platform versus another.
For now, the evidence supports a narrower conclusion: VRC01-class priming has reached proof of concept in humans, while the field is still trying to produce strong serum antibodies and memory B cells that are broad and potent. The review describes progress toward a vaccine strategy, not proof of protective efficacy.
Paper data and sources
Original title: Preclinical and clinical trials for vaccine induction of CD4-binding site neutralizing antibodies.
Authors: Catarina Mendes Silva, Rogier W Sanders, Tom G Caniels
Journal/Repository: Current opinion in HIV and AIDS
Status: Peer-reviewed
First online: 2026-10-01
DOI: 10.1097/coh.0000000000001065
Original paper